AA Multiple randomized trials or meta-analyses, consistent results. How we grade →RCT · 7,020 people with type 2 diabetes and heart disease
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
B Zinman, C Wanner, J Lachin, D Fitchett, E Bluhmki, S Hantel et al. New England Journal of Medicine. 2015.
- In plain language
- EMPA-REG OUTCOME: empagliflozin lowered the main cardiovascular composite (HR 0.86), cardiovascular death by 38% and death from any cause by 32%.
- Limits
- People with diabetes and heart disease, not healthy adults. More genital infections. Funded by Boehringer Ingelheim and Eli Lilly.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Notes on the Blueprint protocol
- Source
- doi.org/10.1056/NEJMoa1504720 · PubMed 26378978
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.